Magnesium Threonate
Phase 3Small molecule
Magnesium Threonate is one of 12 small molecule programs targeting Sleep. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Sleep
#DrugCompanyPhaseTrials
1Ambien
PPurdue Pharma LP
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Hetlioz
VVanda Pharmaceuticals
Phase 3
UBT251
Novo NordiskPhase 3
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Bayer Aspirin
BayerPhase 1
Magnesium Threonate
UUniversity of Miami
Phase 3
Anerem
AAcacia Pharma Ltd
Preclinical
Ketalar
Boehringer IngelheimPreclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Magnesium Threonate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Miami